| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,032 |
5,864 |
$349K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,995 |
2,897 |
$281K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
3,367 |
3,348 |
$137K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,027 |
1,026 |
$83K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
988 |
988 |
$81K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,433 |
1,412 |
$73K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
676 |
676 |
$60K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
620 |
616 |
$48K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
584 |
580 |
$47K |
| S0302 |
Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) |
3,998 |
3,991 |
$36K |
| 90461 |
|
945 |
941 |
$35K |
| 92558 |
|
1,144 |
1,141 |
$28K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
993 |
980 |
$23K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
1,989 |
1,982 |
$21K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
616 |
610 |
$19K |
| 96127 |
|
1,696 |
1,691 |
$17K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,220 |
1,206 |
$16K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,004 |
539 |
$13K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
732 |
728 |
$13K |
| 99173 |
|
419 |
419 |
$7K |
| 87081 |
|
889 |
878 |
$7K |
| 83655 |
|
545 |
543 |
$6K |
| 99177 |
|
494 |
492 |
$6K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
796 |
793 |
$6K |
| 94760 |
|
1,935 |
1,887 |
$4K |
| 36416 |
|
359 |
358 |
$3K |
| 0071A |
|
59 |
59 |
$3K |
| 87634 |
|
19 |
19 |
$1K |
| 99188 |
|
39 |
38 |
$1K |
| 99215 |
Prolong outpt/office vis |
12 |
12 |
$967.15 |
| 0072A |
|
15 |
15 |
$688.20 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
30 |
29 |
$457.80 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
12 |
12 |
$322.32 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
12 |
12 |
$322.32 |
| 81003 |
|
95 |
93 |
$199.16 |
| 99000 |
|
12 |
12 |
$12.00 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
31 |
29 |
$9.00 |